Sorafenib in metastatic MTC – a case report and minireview of the literature

Medullary thyroid cancer (MTC) is a rare and only surgically treatable disease with early development of metastases and bad prognosis. Due to the lack of efficient systemic treatment, new strategies and approaches are needed to better the patients’ outcome. One of the most promising treatment option...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrova, Mila, Mihaylova, Zhasmina, Fakirova, Albena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658222/
https://www.ncbi.nlm.nih.gov/pubmed/23754889
_version_ 1782270233471352832
author Petrova, Mila
Mihaylova, Zhasmina
Fakirova, Albena
author_facet Petrova, Mila
Mihaylova, Zhasmina
Fakirova, Albena
author_sort Petrova, Mila
collection PubMed
description Medullary thyroid cancer (MTC) is a rare and only surgically treatable disease with early development of metastases and bad prognosis. Due to the lack of efficient systemic treatment, new strategies and approaches are needed to better the patients’ outcome. One of the most promising treatment options is the use of tyrosine multikinase inhibitors, which appear to have some effect on the disease progression with tolerable toxicity. Most of them affect many key pathways in the cancer genesis and have proven their effect in different malignancies. We report a case of a young patient with metastatic MTC treated successfully for two months with sorafenib.
format Online
Article
Text
id pubmed-3658222
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36582222013-06-10 Sorafenib in metastatic MTC – a case report and minireview of the literature Petrova, Mila Mihaylova, Zhasmina Fakirova, Albena Int Med Case Rep J Case Report Medullary thyroid cancer (MTC) is a rare and only surgically treatable disease with early development of metastases and bad prognosis. Due to the lack of efficient systemic treatment, new strategies and approaches are needed to better the patients’ outcome. One of the most promising treatment options is the use of tyrosine multikinase inhibitors, which appear to have some effect on the disease progression with tolerable toxicity. Most of them affect many key pathways in the cancer genesis and have proven their effect in different malignancies. We report a case of a young patient with metastatic MTC treated successfully for two months with sorafenib. Dove Medical Press 2010-05-27 /pmc/articles/PMC3658222/ /pubmed/23754889 Text en © 2010 Petrova et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Case Report
Petrova, Mila
Mihaylova, Zhasmina
Fakirova, Albena
Sorafenib in metastatic MTC – a case report and minireview of the literature
title Sorafenib in metastatic MTC – a case report and minireview of the literature
title_full Sorafenib in metastatic MTC – a case report and minireview of the literature
title_fullStr Sorafenib in metastatic MTC – a case report and minireview of the literature
title_full_unstemmed Sorafenib in metastatic MTC – a case report and minireview of the literature
title_short Sorafenib in metastatic MTC – a case report and minireview of the literature
title_sort sorafenib in metastatic mtc – a case report and minireview of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658222/
https://www.ncbi.nlm.nih.gov/pubmed/23754889
work_keys_str_mv AT petrovamila sorafenibinmetastaticmtcacasereportandminireviewoftheliterature
AT mihaylovazhasmina sorafenibinmetastaticmtcacasereportandminireviewoftheliterature
AT fakirovaalbena sorafenibinmetastaticmtcacasereportandminireviewoftheliterature

Ejemplares similares